Table 1.
Summary of the effect of BzATP on the RGC ON-fEPSP and ERG components in the absence and presence of P2X7R antagonists under the physiological conditions tested. All values are expressed as mean ± SEM. See text for n and P values. The effect of BzATP alone is compared to pre-treatment control. The effect of BzATP in the presence of an antagonist is compared to the maximum BzATP-mediated effect
| Physiological Krebs | Modified Krebs (PMSTN) | Low Mg2+ | |
|---|---|---|---|
| RGC ON-fEPSP | – | BzATP: 78.1 ± 3 % | – |
| BzATP + antagonist (% of max. BzATP effect) | |||
| A438079: 68.7 ± 2 % | |||
| A804598: 55.1 ± 11 % | |||
| AF27139: 75.2 ± 7 % | |||
| ERG a-wave | BzATP: 149.0 ± 14 % | BzATP: 70.1 ± 8 % | BzATP: 90.7 ± 3 % |
| BzATP + A438079: 57.3 ± 18 % | BzATP + A438079: 4 ± 16 % | – | |
| ERG b-wave | BzATP: 80.6 ± 4 % | BzATP: 66.6 ± 10 % | BzATP: 89.5 ± 1 % |
| BzATP + A438079: 41.0 ± 30 % | BzATP + A438079: 58.3 ± 16 % | – | |
| ERG OPs | BzATP: 58.8 ± 8 % | – | – |
| BzATP + A438079: 68.2 ± 8 % |
OPs oscillatory potentials